Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1838 studies found for:    "Pancreatic Neoplasms"
Show Display Options
Rank Status Study
1 Completed Randomized Trial of EUS Neurolysis in Pancreas Cancer
Condition: Pancreatic Neoplasms
Intervention: Procedure: Celiac Plexus Neurolysis
2 Completed Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient
Condition: Pancreatic Neoplasms
Interventions: Biological: MV;   Other: Standard Treatment
3 Recruiting Exceptional Responders With Pancreatic Cancer to Chemotherapy
Condition: Pancreatic Neoplasms
Intervention: Drug: Standard of care chemotherapy
4 Recruiting Institut Paoli-Calmettes Pancreatic Neoplasms Database
Condition: Pancreatic Neoplasms
Intervention: Other: Data collection
5 Terminated Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine;   Biological: LAG-3
6 Completed Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
Condition: Pancreatic Neoplasms
Interventions: Drug: Larotaxel (XRP9881);   Drug: 5-Fluorouracil;   Drug: Capecitabine
7 Completed
Has Results
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Biological: DTA-H19
8 Completed
Has Results
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
Condition: Pancreatic Neoplasm
Interventions: Biological: monoclonal antibody;   Drug: chemotherapy
9 Completed Combination With Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Drug: BAY86-9766+Gemcitabine
10 Terminated
Has Results
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: Cisplatin
11 Recruiting Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Drug: mFLOX
12 Completed
Has Results
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine;   Drug: AG-013736
13 Completed Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Drug: hMN14 (labetuzumab)
14 Suspended Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Dietary Supplement: Ketogenic diet
15 Recruiting Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: NC-6004;   Drug: Gemcitabine
16 Not yet recruiting Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Radiation: neoadjuvant short course IMRT;   Radiation: IORT
17 Terminated
Has Results
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
Condition: Pancreatic Neoplasm
Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);   Drug: Placebo;   Drug: Gemcitabine
18 Recruiting Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.
Condition: Pancreatic Neoplasms
Intervention: Radiation: stereotactic radiotherapy
19 Completed A Study for Patients With Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618;   Drug: Gemcitabine
20 Terminated Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study
Condition: Pancreatic Neoplasms
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.